91 related articles for article (PubMed ID: 21551398)
1. Teratogen use in women of childbearing potential: an intervention study.
Morrical-Kline KA; Walton AM; Guildenbecher TM
J Am Board Fam Med; 2011; 24(3):262-71. PubMed ID: 21551398
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
[TBL] [Abstract][Full Text] [Related]
3. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
de Leeuw PW
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
[TBL] [Abstract][Full Text] [Related]
4. Outpatient use of cardiovascular drugs during pregnancy.
Andrade SE; Raebel MA; Brown J; Lane K; Livingston J; Boudreau D; Rolnick SJ; Roblin D; Smith DH; Dal Pan GJ; Scott PE; Platt R
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):240-7. PubMed ID: 18200619
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations].
Lonati C; Morganti A
Pediatr Med Chir; 2009; 31(3):137-9. PubMed ID: 19739495
[No Abstract] [Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. Prescription of teratogenic medications in United States ambulatory practices.
Schwarz EB; Maselli J; Norton M; Gonzales R
Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908
[TBL] [Abstract][Full Text] [Related]
8. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age.
Martin U; Foreman MA; Travis JC; Casson D; Coleman JJ
J Clin Pharm Ther; 2008 Oct; 33(5):507-11. PubMed ID: 18834365
[TBL] [Abstract][Full Text] [Related]
9. Uptake of angiotensin II receptor blockers in the treatment of hypertension.
Greving JP; Denig P; van der Veen WJ; Beltman FW; Sturkenboom MC; de Zeeuw D; Haaijer-Ruskamp FM
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):461-6. PubMed ID: 15912393
[TBL] [Abstract][Full Text] [Related]
10. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
[TBL] [Abstract][Full Text] [Related]
11. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.
Kheterpal S; Khodaparast O; Shanks A; O'Reilly M; Tremper KK
J Cardiothorac Vasc Anesth; 2008 Apr; 22(2):180-6. PubMed ID: 18375317
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
13. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
Hudson M; Richard H; Pilote L
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
[TBL] [Abstract][Full Text] [Related]
14. Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some?
Wong J; Molyneaux L; Constantino M; Twigg SM; Yue DK
Diabetes Obes Metab; 2010 Dec; 12(12):1072-8. PubMed ID: 20977578
[TBL] [Abstract][Full Text] [Related]
15. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Malde B; Regalado J; Greenberger PA
Ann Allergy Asthma Immunol; 2007 Jan; 98(1):57-63. PubMed ID: 17225721
[TBL] [Abstract][Full Text] [Related]
16. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Quan A
Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of antihypertensive drugs and risk of cancer.
Assimes TL; Elstein E; Langleben A; Suissa S
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1039-49. PubMed ID: 18780400
[TBL] [Abstract][Full Text] [Related]
18. Avoidance of ACE inhibitors or angiotensin receptor blockers among women of childbearing potential with diabetes.
Guirguis AB; Shilliday BB; Malone RM; Pignone MP
Diabetes Res Clin Pract; 2008 Jan; 79(1):e11-2. PubMed ID: 17716774
[No Abstract] [Full Text] [Related]
19. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
de Jong-van den Berg LT; Bakker MK; de Walle HE; van den Berg PB
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2222-3. PubMed ID: 17061436
[No Abstract] [Full Text] [Related]
20. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
